[1]柴虹,蒋周芩,舒茂琴,等.CRT-P/D治疗射血分数降低的心力衰竭患者超反应发生的相关因素分析[J].第三军医大学学报,2018,40(09):810-815.
 CHAI Hong,JIANG Zhouqin,SHU Maoqin,et al.Analysis on factors related to super-response events in heart failure patients with reduced ejection fraction by CRT-P/D therapy[J].J Third Mil Med Univ,2018,40(09):810-815.
点击复制

CRT-P/D治疗射血分数降低的心力衰竭患者超反应发生的相关因素分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第09期
页码:
810-815
栏目:
临床医学
出版日期:
2018-05-15

文章信息/Info

Title:
Analysis on factors related to super-response events in heart failure patients with reduced ejection fraction by CRT-P/D therapy
作者:
柴虹蒋周芩舒茂琴邓盛荣周扬宋治远李林峪
陆军军医大学(第三军医大学)第一附属医院心血管内科
Author(s):
CHAI Hong JIANG Zhouqin SHU Maoqin DENG Shengrong ZHOU Yang SONG Zhiyuan LI Linyu

Department of Cardiology, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400038, China

关键词:
心脏再同步化治疗心力衰竭超反应
Keywords:
cardiac resynchronization therapy heart failure super-response
分类号:
R181.32; R331.31; R541.6
文献标志码:
A
摘要:

目的    探讨心脏再同步化治疗(cardiac resynchronization therapy with pacemaker function/defibrillation function,CRT-P/D)在射血分数降低的心力衰竭患者中发生超反应的预测因素及不良事件的影响因素。方法    回顾分析我科2015年1月至2017年1月收治的59例因心力衰竭采用CRT-P/D治疗并随访12个月以上的患者,采集一般临床资料、心电图、心脏超声、不良事件发生等临床数据。以术后12个月左室射血分数(left ventricular ejection fraction,LVEF)升高幅度分3组:超反应组(幅度≥15%,14例),中度反应组(5%≤幅度<15%,23例),轻度/无反应组(幅度<5%,22例)。采用方差分析及多因素Logistic回归分析筛选CRT-P/D治疗发生超反应的独立预测因素。采用KaplanMeier法进行预后分析,COX回归模型明确影响预后的危险因素。结果    超反应组术前心房颤动比例、右房内径(right atrial diameter,RA)明显低于中度反应组及轻度/无反应组(P<0.05),双心室起搏比例明显高于中度反应组及轻度/无反应组(P<0.01)。多因素Logistic回归结果显示病程<1.5年(OR=17.54,95%CI=1.41~216.96,P=0.02)、RA<35 mm(OR=23.70,95%CI=1.60~349.32,P=0.02)、双心室起搏比例>96%(OR=36.35,95%CI=12.17~609.03,P=0.01)是术后发生超反应的独立预测因素。预后分析显示无事件(心衰再住院、恶性心律失常、全因死亡)生存率超反应组高于中度反应组及轻度/无反应组(Log Rank:P<0.01),多因素Cox回归分析显示对于复合不良事件的发生,心房颤动是影响预后的独立因素(P<0.05,HR=2.35,95%CI=1.067~5.19)。结论    对于CRT-P/D治疗射血分数降低的心力衰竭患者,病程<1.5年、RA<35 mm,双心室起搏比率>96%是发生超反应的重要预测因素,心房颤动是影响术后不良事件发生的独立因素。

Abstract:

Objective    To analyze the influencing factors for the occurrence of super-response and adverse events in heart failure patients with reduced ejection fraction by cardiac resynchronization therapy with pacemaker/defibrillation (CRT-P/D) therapy. Methods    A retrospective analysis was performed on 59 heart failure patients undergoing CRT-P/D therapy in our department from January 2015 to January 2017. All the patients were followed up for more than 12 months. Their general information, electrocardiogram, echocardiogram, and adverse events were collected and analyzed. According to the elevation of left ventricular ejection fraction (LVEF) at 12 months postoperatively, these patients were divided into superresponse group (range ≥15%, n=14), moderate-response group (5%~15%, n=23), and mild/nonresponse group (<5%, n=22). ANOVA and multivariate logistic regression analysis were used to screen independent factors for super-response events due to CRT-P/D therapy. Kaplan-Meier analysis was adopted for prognostic analysis, and COX regression model was used to further identify the risk factors for prognosis. Results     For the super-response group, the proportion of atrial fibrillation and the diameter of right atrial (RA) was significantly lower and smaller (P<0.05), while the proportion of biventricular pacing was obviously higher than those in the moderate- and mild/non-responde groups (P<0.01). Multivariate logistic regression results showed that the disease course <1.5 years (OR=17.54, 95%CI: 1.41~216.96, P=0.02), RA<35 mm (OR=23.70, 95%CI: 1.60~349.32, P=0.02), proportion of biventricular pacing >96% (OR=36.35, 95%CI: 12.17~609.03, P=0.01) were independent prognostic factors for occurrence of super-response events after surgery. Prognostic analysis showed that there were more patients obtaining event-free survival (heart failure hospitalization, malignant arrhythmia, or all-cause death) in the super-response group than the moderate and mild/non-response groups (Log Rank P<0.01). Multivariate Cox regression analysis indicated that atrial fibrillation was an independent factor for prognosis (P<0.05, HR=2.35, 95%CI: 1.067~5.190). Conclusion    For the heart failure patients with reduced ejection fraction and undergoing CRT-P/D therapy, disease course <1.5 years, RA <35 mm, and biventricular pacing proportion >96% are important predictive factors for occurrence of super-response events. Atrial fibrillation is an independent factor for postoperative adverse events.

参考文献/References:

[1]BRIGNOLE M,AURICCHIO A,BARONESQUIVIAS G,et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)[J]. Europace,2013,15(8):1070-1118. DOI: 10.1093/europace/eut206.
[2]EPSTEIN A E,DIMARCO J P,ELLENBOGEN K A,et al. ACC/AHA/HRS 2008 Guidelines for devicebased therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices):developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons[J]. Circulation, 2008,117(21): e350-e408. DOI: 10.1161/CI=RCUALTIONAHA.108.189742.
[3]CLELAND J G,ABRAHAM W T,LINDE C,et al. An individual patient metaanalysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure[J]. Eur Heart J, 2013, 34(46):3547-3556. DOI:10.1093/eurheartj/eht290.
[4]WELLS G, PARKASH R, HEALEY J S,et al. Cardiac resynchronization therapy: a metaanalysis of randomized controlled trials[J]. CMAJ,2011,183(4):421-429. DOI:10.1503/cmaj.101685.
[5]LINDE C,ABRAHAM W T,GOLD M R,et al. Predictors of shortterm clinical response to cardiac resynchronization therapy[J]. Eur J Heart Fail,2017,19(8):1056-1063. DOI:10.1002/ejhf.795.
[6]EPSTEIN A E, DIMARCO J P, ELLENBOGEN K A,et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for devicebased therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol,2013,61(3):e6-e75. DOI:10.1016/j.jacc.2012.11.007.
[7]YU C M,BLEEKER G B,FUNG J W,et al. Left ventricular reverse remodeling but not clinical improvement predicts longterm survival after cardiac resynchronization therapy[J]. Circulation, 2015, 112(11):1580-1586. DOI:10.1161/CI=RCULATIONAHA.105.538272.
[8]KILLU A M,GRUPPER A,FRIEDMAN P A,et al. Predictors and outcomes of “superresponse” to cardiac resynchronization therapy[J]. J Card Fail, 2014, 20(6):379-386.DOI: 10.1016/j.cardfail.2014.03.001.
[9]BLEEKER G B,SCHALIJ M J,BOERSMA E,et al. Does a gender difference in response to cardiac resynchronization therapy exist? [J]. Pacing Clin Electrophysiol,2005,28(12):1271-1275.DOI: 10.1111/j.15408159.2005.00267.x.
[10]REANT P,ZAROUI A,DONAL E,et al. Identification and characterization of superresponders after cardiac resynchronization therapy[J]. Am J Cardiol,2010,105(9):1327-1335. DOI: 10.1016/j.amjcard.2009.12.058.
[11]GASPARINI M,REGOLI F,CERIOTTI C,et al. Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy:temporal pattern and clinical predictors[J]. Am Heart J,2008,155(3):507-514. DOI: 10.1016/j.ahj.2007.10.028.
[12]YPENBURG C,ROES S D,BLEEKER G B,et al. Effect of total scar burden on contrastenhanced magnetic resonance imaging on response to cardiac resynchronization therapy [J]. Am J Cardiol, 2007, 99(5):657-660. DOI:10.1016/j.amjcard.2006.09.115.

相似文献/References:

[1]王江,田颖,宋熔,等.心力衰竭患者心肌组织ACE2和ACE基因表达[J].第三军医大学学报,2007,29(10):945.
 WANG Jiang,TIAN Ying,SONG Rong,et al.ACE2 and ACE gene expression in myocardium of congestive heart failure[J].J Third Mil Med Univ,2007,29(09):945.
[2]王逵,杨成明,刘国通,等.FKBP12.6基因转染对心衰犬心功能及心肌病理变化的影响[J].第三军医大学学报,2008,30(05):431.
 WANG Kui,YANG Cheng-ming,LIU Guo-tong,et al.Effects of FKBP12.6 gene transfection on cardiac function and myocardium pathomorphology in canine with heart failure[J].J Third Mil Med Univ,2008,30(09):431.
[3]姜大春,张倩,何国祥,等.心动过速性心肌病临床诊断及防治[J].第三军医大学学报,2007,29(10):969.
[4]梅霞,郑向清,田颖,等.福辛普利和美托洛尔对心力衰竭患者心肌重构和血浆神经激素水平的影响[J].第三军医大学学报,2006,28(18):1897.
[5]熊德高,石建,曾安宁.大剂量速尿持续静滴并输入高渗盐水救治严重心力衰竭20例的疗效[J].第三军医大学学报,2006,28(15):1629.
[6]耿召华,刘春燕,李隆贵,等.卡维地洛对心肌梗死后心衰大鼠心肌肌浆网Ca2+泵活性和Ca2+释放通道密度的影响[J].第三军医大学学报,2009,31(06):522.
 GENG Zhao-hua,LIU Chun-yan,LI Long-gui,et al.Carvedilol improves Ca2+ pump activity and Ca2+ release channels density in myocardial sarcoplasmic reticulum of rats with chronic heart failure caused by myocardial infarction[J].J Third Mil Med Univ,2009,31(09):522.
[7]刘启亮,宋耀明,刘超.Neuregulin-1β对阿霉素致心衰大鼠心肌细胞凋亡及bax、bcl-2蛋白表达的干预效应[J].第三军医大学学报,2009,31(24):2448.
 LIU Qi-liang,SONG Yao-ming,LIU Chao.Neuregulin-1β inhibits cardiomyocyte apoptosis in adriamycin-induced rat cardiomyopathy by regulating bcl-2 and bax[J].J Third Mil Med Univ,2009,31(09):2448.
[8]刘春燕,钟杭美,罗昭林,等.冠心病心力衰竭患者血压昼夜节律的变化对心率变异性的影响[J].第三军医大学学报,2010,32(12):1371.
[9]蔡伦安,卢永昕,苏冠华,等.己酮可可碱对慢性心力衰竭患者细胞因子免疫调节及B型利钠肽的影响[J].第三军医大学学报,2010,32(17):1902.
[10]赵国忠,陈晨,黄赞维,等.维持性血透患者心力衰竭危险因素的Logistic回归分析[J].第三军医大学学报,2008,30(19):1855.
 ZHAO Guo-zhong,CHEN Chen,HUANG Zan-wei,et al.Logistic regression analysis of risk factors for heart failure in hemodialysis patients[J].J Third Mil Med Univ,2008,30(09):1855.

更新日期/Last Update: 2018-05-11